Zhang et al. have shown that aneuploidy CD31− CTC and CD31+ CTEC may be used as a pair of biomarkers for circulating cell tumors to predict patients with non-small-cell lung cancer receiving antiangiogenesis combined therapy [40]. The gene discussed is PECAM1; the disease is non-small cell lung carcinoma.